Jakavi 15mg Tablet contains Ruxolitinib, a potent Janus kinase (JAK) inhibitor indicated for the treatment of myelofibrosis, polycythemia vera, and other related myeloproliferative disorders. Ruxolitinib selectively inhibits JAK1 and JAK2 enzymes, which play a critical role in the signaling pathways involved in hematopoiesis and immune function. By modulating these pathways, Jakavi helps reduce splenomegaly, alleviate disease-related symptoms such as fatigue, night sweats, and pruritus, and improve overall quality of life in affected patients. The 15mg dosage is typically administered orally twice daily, with dose adjustments based on clinical response and hematologic parameters. Common adverse effects include anemia, thrombocytopenia, and increased susceptibility to infections; therefore, regular monitoring of blood counts and liver function tests is recommended during therapy. Jakavi is contraindicated in patients with known hypersensitivity to Ruxolitinib or its excipients and should be used cautiously in individuals with active infections or hepatic impairment. This medication should be prescribed and managed by healthcare professionals experienced in the treatment of myeloproliferative neoplasms to ensure optimal therapeutic outcomes and minimize potential risks. Patient education regarding adherence and monitoring is essential for safe and effective use of Jakavi 15mg Tablet.